DeepScribe vs Heidi Health (2026)
Both claim conversation support in roughly 110 languages, so for once in this lane language settles nothing. The grades settle plenty: DeepScribe holds an A on clinical evidence against Heidi's C, on the strength of a 98.8 KLAS Emerging Company Spotlight score and a published oncology study, and an A on EHR depth against Heidi's C, writing discrete fields bidirectionally where Heidi's push to chart is reported as gated to upper tiers. What Heidi holds is reach and transparency: a reported 190 countries and more than 200 specialties, published pricing from a free tier, and a platform expanding into cited decision support through Heidi Evidence, where DeepScribe sells through enterprise sales with no trial. If your failure mode is complex specialty documentation, oncology above all, with evidence a committee will accept, start with DeepScribe. If your failure mode is geography, a price you can see, or a caseload spread across many specialties rather than deep in one, start with Heidi, and confirm the BAA and write back tier gates before contracting.
- Specialty depth over specialty count: oncology as its center of gravity with a reported 40 percent of US cancer care visits and tuned models for six further specialties, against Heidi's breadth claim of more than 200 specialties without published depth in any one.
- The grades split hard in its favor: an A on clinical evidence against Heidi's C, on a 98.8 KLAS Emerging Company Spotlight score and a published oncology study, and an A on EHR depth against Heidi's C, writing discrete fields bidirectionally where Heidi's push to chart is reported as gated to upper tiers.
- Coding lives in the note: HCC, CPT, and ICD-10 suggestions built in, with chart context read before the visit and structured data written after.
- Geography and reach: a reported 190 countries and more than 200 specialties on 2.5 million consults a week, where DeepScribe's center of gravity is US specialty care.
- You need a price without a sales call: a free tier with unlimited transcription and a published Clinician tier at $150 per user per month billed annually, where DeepScribe runs enterprise sales with no self serve signup and no trial.
- The platform is expanding under you: Heidi Evidence surfaces cited clinical decision support from BMJ, NICE, and HealthPathways at the point of care, and Heidi Comms coordinates patient calls, on a company that raised a $65 million Series B in late 2025.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. DeepScribe and Heidi Health are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | DeepScribe | Heidi Health |
|---|---|---|
| Primary category | Ambient Scribes | Ambient Scribes |
| Founded | 2017 | Not recorded |
| Headquarters | San Francisco, California | Melbourne, Australia |
| Website | deepscribe.ai | heidihealth.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards DeepScribe its top capability grade on several axes, including AI Centrality, Clinical and Operational Evidence and EHR and Interoperability Depth. Set against Heidi Health, DeepScribe grades higher on Clinical and Operational Evidence, HIPAA and BAA Posture and EHR and Interoperability Depth. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Heidi Health its top capability grade on several axes, including AI Centrality, AI Safety and PHI Stewardship and Security Certifications and Trust Center. Set against DeepScribe, Heidi Health grades higher on several axes, including AI Safety and PHI Stewardship, Security Certifications and Trust Center and AI Governance and Bias Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose DeepScribe or Heidi Health?
On the axes where the AI Health Index separates them, DeepScribe grades higher on Clinical and Operational Evidence, HIPAA and BAA Posture and EHR and Interoperability Depth, and Heidi Health grades higher on several axes, including AI Safety and PHI Stewardship, Security Certifications and Trust Center and AI Governance and Bias Disclosure. Heidi Health leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do DeepScribe and Heidi Health differ most?
The widest separation the AI Health Index records between DeepScribe and Heidi Health is on Clinical and Operational Evidence, where DeepScribe grades A and Heidi Health grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do DeepScribe and Heidi Health grade the same?
The AI Health Index grades DeepScribe and Heidi Health the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Ambient Scribes page.
Volume and coverage figures for both vendors are vendor published, including both language claims, DeepScribe's oncology share, and Heidi's weekly consult count. DeepScribe's KLAS scores are buyer survey based, and the Emerging Company Spotlight is a different KLAS instrument from the Best in KLAS category awards held elsewhere in this lane.
Heidi's clinical evidence grades C, with third party review candid that multi problem visits document less reliably than single problem encounters and no accuracy study against ground truth retrieved. Two Heidi tier gates matter for US buyers: the organization wide Business Associate Agreement and EHR write back are both reported as available only from the Practice tier upward; Heidi's pricing was also restructured in February 2026 with sources conflicting on some tier amounts. Heidi's pricing is published; DeepScribe publishes none, with third party estimates of $350 to $500 per provider per month recorded as unconfirmed.